

Age of Onset

All sections on this page are required unless otherwise specified. Important fields are highlighted. Incomplete information could result in a delay of testing.

| PATIENT INFORMATION | | | | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|------------------------------|--|--|
| First Name | Last Name | | | |
| Sex Assigned at Birth: Male Female | Date of Birth (mm/dd | /уу) | | |
| Patient Karyotype (if known): | | | | |
| Gender Identification (optional): | | | | |
| Email | | | | |
| Address | | | | |
| City | State | Zip Code | | |
| Primary Phone | Is this patient decease Deceased Date: | ed? O Yes O No | | |
| | | | | |
| SAMPLE INI | FORMATION | | | |
| Date Sample Collected (mm/dd/yy) | Medical Record # | | | |
| OBlood (peripheral) Other (including lab and specify | g buccal, cord blood, ar source): | nd isolated DNA; <u>call</u> | | |
| Patient has had a blood transfusion OYes ((2-4 weeks of wait time is required for some to | · . | ansfusion: | | |
| | | 0 | | |
| Patient has had an allogeneic bone marrow transplant () Yes () No For exome-based tests, fibroblasts are required for patients who had an allogeneic bone marrow transplant. GenomeXpress* is not a suitable test for patients who had an allogeneic bone marrow transplant. See www.genedx.com/specimen-requirements for details. | | | | |
| | | | | |
| STATEMENT OF M | EDICAL NECESSI | ТҮ | | |
| By submission of this test requisition and accompanying sample(s), I: (i) authorize and direct GeneDx to perform the testing indicated; (ii) certify that the person listed as the ordering provider is authorized by law to order the test(s) requested; (iii) certify that any custom panel and/or ordered test(s) requested on this test requisition form are reasonable and medically necessary for the diagnosis and/or treatment of a disease, illness, impairment, symptom, syndrome or disorder; (iv) the test results will determine my patient's medical management and treatment decisions of this patient's condition on this date of service; (v) have obtained this patient's and relatives', when applicable, written informed consent to undergo any genetic testing requested; and (vi) that the full and appropriate diagnosis code(s) are indicated to the highest level of specificity. | | | | |
| Signature of Ordering Provider | | Date | | |
| | | | | |
| PATIENT (| CONSENTS | | | |
| By signing this form, I acknowledge as the patient or relative being tested that I have read or have had read to me the GeneDx Informed Consent document at the end of this test requisition form, and understand the information regarding molecular genetics testing. I have had the opportunity to ask questions about the testing, the procedure, the risks, and the alternatives. By signing this form, I authorize GeneDx to perform genetic testing as ordered. I understand that, for tests that evaluate data from multiple family members concurrently, test results from these family members may be included in a single comprehensive report that will be made available to all tested individuals and their healthcare providers. | | | | |
| More information, including the GeneDx Notic website: www.genedx.com | e of Privacy Policies, is o | available on GeneDx's | | |
| By checking this box, I confirm that I am a New York State resident, and I give permission for GeneDx to retain any remaining sample longer than 60 days after the completion of testing, and to be used as a de-identified sample for test development and improvement, internal validation, quality assurance, and training purposes. Otherwise, New York law requires GeneDx to destroy my sample within 60 days, and it cannot be used for test development studies. | | | | |

☐ Check this box if you wish to opt out of being contacted for research studies
☐ Check this box if you do not wish to receive ACMG secondary findings (Full Exome Sequencing and Genome Sequencing Tests ONLY; not for Xpanded® or Slice tests).

Date

Date

Date

| GeneDx Account Number | Account Name | • | | |
|----------------------------------------------|--------------|--------------|--|--|
| Phone | Fax | Fax | | |
| Address | | | | |
| City | State | Zip Code | | |
| Ordering Provider Name | | Role/Title | | |
| NPI | Phone Number | Phone Number | | |
| Send Report Via: Fax Email I Fax #/Email: | Portal | | | |
| Additional Ordering Provider Name (op | otional) | Role/Title | | |
| NPI | | | | |
| Send Report Via: | Portal | | | |
| SEND ADDITIONAL REPORT COPIES TO (o | ptional) | | | |
| Provider Name | GeneDx Acct# | | | |
| Fax #/Email: | | | | |

| PAYMENT OPTIONS (Select One) | | | | | | |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--|--|--|--|
| O PATIENT BILL | If Patient Bill is selected, I am electing to be treated as a self-pay patient for this testing. I agree that neither GeneDx nor I will submit a claim to my insurance for this testing, if I have insurance. GeneDx will send an invoice to the patient listed above. | | | | | |
| | Authorized Patient/Guardian Signature | | | | | |
| O INSTITUTIONAL BILL | GeneDx Account # Hospital/Lab Name | Place Sticker/Stamp Here | | | | |

Signature of Patient/Legal Guardian (required)

Signature of Relative A/Legal Guardian

Signature of Relative B/Legal Guardian

ICD-10-CM Codes
Clinical Diagnosis



| First Name | Last Name | Date of Birth |
|------------|-----------|---------------|
| | | |

DIRECTIONS TO ORDER RAPID TESTING

- $\bullet \ \, \text{Client must email GeneDx at Xpress@genedx.com for all rapid testing cases prior to samples arriving }$
- Trios (proband and both biological parents) are strongly recommended for rapid tests to increase diagnostic yield and to reduce the number of variants of uncertain significance (VUS)
- Parental samples must be sent with the proband sample
- Fresh blood samples are the preferred specimen type
- Institutional or Self-Pay only

| XPRESS TESTING | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------|--------------------------------------------------------------------------------------------------------------------|--|--|
| Provisional results will be available within 7 calendar days after the proband and biological parental samples are received. International clients will receive an email status update at 7 days. Please be sure to provide contact information for the provisional results: | | | | | |
| • Contact No | rame: Phone results report will be sent to the ordering provider within ap | : | Email: | | |
| • The written | results report will be sent to the ordering provider within ap | proximately 14 | days. | | |
| TEST CODE | TEST NAME | TEST CODE | TEST NAME | | |
| XomeDxXpress® (Trios recommended) GenomeXpress® (Trios recommended) | | | | | |
| □896a | XomeDxXpress® Trio* | ☐ TH78a | GenomeXpress® Trio* | | |
| □690c | Mitochondrial Genome Sequencing & Deletion Testing (Concurrent) [‡] | | Accepted specimen: Proband - peripheral blood only. Relatives - peripheral blood preferred; buccal accepted. | | |
| □896e | XomeDxXpress® Duo* | □TH78e | GenomeXpress® Duo* | | |
| □690c | Mitochondrial Genome Sequencing & Deletion Testing (Concurrent) [‡] | | Accepted specimen: Proband - peripheral blood only. Relative - peripheral blood preferred; buccal accepted. | | |
| □896b | XomeDxXpress® Proband | □TH78b | GenomeXpress® Proband | | |
| □ 690c | Mitochondrial Genome Sequencing & Deletion Testing (Concurrent) [‡] | | Accepted specimen: Proband - peripheral blood only. | | |
| NICUXpress | | | | | |
| □ TL27 | NICUXpress Panel | | | | |
| * If a Trio or Duo test is ordered, please fill out the Family Member Samples to be Included in Testing section on the next page ‡Exame and mito genome will be reported secarately | | | | | |

(Continue to next page)

GeneDx tests are frequently updated and improved based upon the most recent scientific evidence. The test codes, genes, and gene quantities listed on this test requisition are subject to change by GeneDx at any time. The most current test menu and list of genes included for a specific test panel may be found on our website, genedx.com. Please note that GeneDx reserves the right to modify and upgrade any ordered panel to the version currently listed on our website.

| First Name | | | Last | ime | | Date of Birth | |
|------------------------|---------------------------------------------------------|-------------------------|----------------------------|-------------------------------------------------|----------------------|-------------------------------------------------|-----------------------|
| | | | FAMILY M | MBER SAMPLES TO B | E INCLUDED IN 1 | ESTING | |
| FAMILY MEN | MBER INFORMATION M | UST BE PROV | | | | KS FOR INCLUSION IN THE PROBAND'S TEST | Ordered test |
| | require adjusting to a estigations. Family me | | | | es received. A chanç | ge in the ordered test will impact billing, inc | luding prior |
| | First Name | Las | st Name | DOB | O Asympto | omatic O Symptomatic | |
| Biological | | | | | | Dx (Accession #: |) |
| Mother | | | | | | able O To be sent within 3 weeks | |
| | First Name | Las | st Name | DOB | O Asympto | omatic O Symptomatic | |
| Biological Father | | | | | O At Gene[| Dx (Accession #: |) |
| ratio | | | | | O Not avail | able O To be sent within 3 weeks | |
| | Relationship to Proband | | | | | | |
| Other | First Name | Las | st Name | DOB | O Asympto | omatic O Symptomatic | |
| Biological Relative | | | | | _ | Ox (Accession #: |) |
| | | | | | O Not avail | able O To be sent within 3 weeks | |
| | | | | EANWY LUCK | 0.DV# | | |
| | | *т | his section is | FAMILY HIST ot intended for ordering of | | esting report. | |
| □ No Know | vn Family History | □P€ | edigree Atto | hed D | Adopted | | |
| R | elationship | Maternal | Paternal | | Relevant | History | Age at Dx |
| 1 | | 0 | 0 | | | | |
| 2 | | 0 | 0 | | | | |
| 3 | | 0 | 0 | | | | |
| | | <u>'</u> | - | | | | _ |
| | | *T | hio opašion is | PREVIOUS GENETIC | | asting various | |
| Personal o | or family history of g | | | ot intended for ordering of Yes (If yes, please | - | | |
| | , , , | | | · · · · · · · · · · · · · · · · · · · | <u> </u> | | |
| | • | g, etc.), Ge | netic Test(s | and Result (e.g. positiv | e, negative, etc.). | If relative was tested at GeneDx, plea | se also |
| provide th | eir accession #: | | | | | | |
| | | | | | | | |
| If patient o | or relative(s) were for ny Variants of Intere | ound to havest‡ via the | ve a positiv checkbox k | or VUS result on prior t low. | esting, please pro | ovide details below. | |
| Relation (s | self, sibling, etc.) | Gene | Transcrip | t c./p. (SNV) or | exon#(CNV) | Build, coordinates (CNV) | Variant of Interest‡? |
| 1 | | | | | | | |
| 2 | | | | | | | |
| 3 | | | | | | | |
| • | sequence variants: gene, CNVs: gene, transcript #, e | | | 1 | | 1 | I |
| | 3, aopt 11,1 | <u>o.,</u> ou | ., | | | | |

(Continue to next page)

‡ For certain tests, GeneDx **may** be able to specifically comment upon the presence or absence of previously identified variant(s) of interest in the report. Complete variant information must be provided in the table above at the time the test order is placed. If you do not complete the table above and check off that a previously identified variant is a variant of interest, it will not be possible to comment upon the presence or absence of the variant in the report retrospectively. This service is not applicable to targeted variant testing.



First Name Last Name Date of Birth

| CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED) Relevant clinical records are required at the time of sample submission to ensure the information is included in data analysis. | | | | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-------------------------------------------------|--|--|--|
| Genes of interest: | | | | | |
| | | | | | |
| Differential diagnosis: | | | | | |
| | | | | | |
| Pre/Perinatal History | Neurological Findings | Hearing Impairment | | | |
| Cystic hygroma | ☐ Abnormality of nervous system | Abnormal newborn screen: | | | |
| □ Diaphragmatic hernia | □ Ataxia | ☐ Conductive hearing impairment | | | |
| □ Encephalocele □ Growth delay | □ Cerebral palsy □ Chorea | ☐ Sensorineural hearing impairment | | | |
| ☐ Increased nuchal translucency | ☐ Critical visual impairment | | | | |
| ☐ Intrauterine growth retardation | □ Dementia | Endocrine Findings | | | |
| □ Nonimmune hydrops fetalis | □ Dysarthria | □ Delayed puberty | | | |
| Oligohydramnios | , □ Dyskinesia | □ Diabetes Insipidus | | | |
| □ Omphalocele | □ Dysphasia | □ Diabetes mellitus □ Hyperthyroidism | | | |
| □ Polyhydramnios | □ Dystonia | ☐ Hypophosphatemia | | | |
| Prematurity GA: | ☐ Encephalopathy | Hypothyroidism | | | |
| □ Prolonged neonatal jaundice | ☐ Headaches | ☐ Maturity-onset diabetes of the young | | | |
| | ☐ Hemiplegia | □Rickets | | | |
| Structural Brain Abnormalies | □ Infantile Spasms □ Migraines | | | | |
| ☐ Abnormal myelination | ☐ Myoclonus | Description Findings | | | |
| ☐ Abnormality of basal ganglia | □ Parkinsonism | Respiratory Findings | | | |
| ☐ Abnormality of brainstem | ☐ Peripheral neuropathy | □ Asthma | | | |
| ☐ Abnormality of periventricular white matter | □ Seizures , | ☐ Bronchiectasis ☐ Hyperventilation | | | |
| Abnormality of the corpus callosum | ☐ Sensory neuropathy | ☐ Hypoventilation | | | |
| ☐ Aplasia/hypoplasia of cerebellar vermis | □ Spasticity | | | | |
| □ Aplasia/hypoplasia of cerebellum □ Arnold Chiari malformation | Syncope | ☐ Pulmonary fibrosis | | | |
| ☐ Cerebellar atrophy | ☐ Tremors | □ Respiratory insufficiency | | | |
| Heterotopia (periventricular nodular | □ Vertigo | | | | |
| heterotopia) | | Hematologic or Immunologic Findings | | | |
| □ Holoprosencephaly | Craniofacial/Dysmorphism | ☐ Allergic rhinitis | | | |
| □Hydrocephalus | ☐ Abnormal facial shape (dysmorphic | ☐ Anemia | | | |
| □ Leukodystrophy | features) Specify: | — ☐ Immunodeficiency | | | |
| Lissencephaly | ☐ Brachycephaly | □ Neutropenia ' | | | |
| □ Pachygyria | ☐ Cleft lip and/or palate | □ Pancytopenia | | | |
| □ Polymicrogyria | Coarse facial features | ☐ Recurrent infections | | | |
| □ Ventriculomegaly | □ Craniosynostosis □ Macrocephaly | □Thrombocytopenia | | | |
| | ☐ Microcephaly | | | | |
| Developmental/Behavioral Findings | ☐ Short neck | Skin/Hair Findings | | | |
| ☐ Absent speech | Synophrys | ☐ Abnormal blistering of the skin | | | |
| □ Aggressive behavior | | ☐ Abnormality of nail | | | |
| □ Anxiety | Eye Defects/Vision | □ Alopecia · | | | |
| ☐ Autistic behavior | | ☐ Anhidrosis | | | |
| □ Cognitive impairment □ Delayed speech & language development | ☐ Abnormality of vision ☐ Anophthalmia | □ Café-au-lait macules | | | |
| ☐ Developmental regression | ☐ Cataracts | □ Coarse hair | | | |
| □ Dysarthria | □ Coloboma | □ Cutis laxa □ Eczema | | | |
| Gait disturbance | □ Corneal opacity | ☐ Hemangiomas | | | |
| ☐ Global developmental delay | Ectopia lentis ′ | ☐ Hyperextensible skin | | | |
| ☐ Hyperactivity . | □ External ophthalmoplegia | ☐ Hyperpigmentation of the skin | | | |
| ☐ Incoordination | ☐ Microphthalmia | ☐ Hypohidrosis | | | |
| Intellectual disability | Myopia | ☐ Hypopigmentation of the skin | | | |
| Learning disability | □ Nystagmus | □Ichthyosis | | | |
| ☐ Memory impairment | □ Optic atrophy □ Optic neuropathy | ☐ Skin rash | | | |
| ☐ Sleep disturbance ☐ Stereotypy | ☐ Ptosis | ☐ Sparse hair | | | |
| _ storeotypy | ☐ Retinal detachment | □ Telangiectasia □ Vascular skin abnormality | | | |
| | □ Retinitis pigmentosa | ☐ Vascular skin abhormality ☐ Velvety skin | | | |
| | □ Strabismus | = 101701, OMIT | | | |



First Name Last Name Date of Birth

| CLINICAL INFORMATION (DETAILED MEDICAL RECORDS MUST BE ATTACHED) | | | |
|------------------------------------------------------------------|-------------------------------------------|---------------------------------------------|--|
| Cardiac Findings | Musculoskeletal Findings | Vascular System | |
| ☐ Abnormal heart morphology | ☐ Abnormal connective tissue | □Aneurysm | |
| □ Amyloidosis | ☐ Abnormal form of the vertebral bodies | ☐ Arterial calcification | |
| □ Aortic root dilation | ☐ Abnormality of the ribs | ☐ Arterial dissection | |
| □ Arrhythmia | □ Arachnodactyly | ☐ Arterial tortuosity | |
| ☐ Atrial septal defect | □ Arthralgia | ☐ Arteriovenous malformation | |
| ☐ Bicuspid aortic valve | ☐ Arthrogryposis | □ Epistaxis | |
| □ Bradycardia | ☐ Bruising susceptibility | Lymphedema | |
| ☐ Coarctation of aorta | ☐ Clinodactyly | ☐ Pulmonary hypertension | |
| ☐ Dilated cardiomyopathy | Decreased muscle mass | □ Stroke | |
| Heterotaxy | □ Ectrodactyly | | |
| □ Hypertension | □ Exercise intolerance | | |
| ☐ Hypertrophic cardiomyopathy | ☐ Fatigue | Cancer | |
| ☐ Mitral valve prolapse | ☐ Hemihypertrophy | | |
| ☐ Noncompaction cardiomyopathy | ☐ Hypertonia | □Type: Location: | |
| □ Patent ductus arteriosis | Hypotonia | Location: | |
| □ Patent foramen ovale | ☐ Joint hypermobility | Age of onset: | |
| ☐ Prolonged QTc interval | ☐ Muscle weakness | | |
| ☐ Sudden death | □Myalgia | | |
| ☐ Tetralogy of Fallot | ☐ Myopathic facies | | |
| □ Ventricular septal defect | □Myopathy | Other Testing/Imaging | |
| □ Ventricular tachycardia | Osteoarthritis | (Please provide copy or report if possible) | |
| , | □ Osteopenia | □ Faha: | |
| | □ Pain · | ☐ Echo: | |
| | □ Pectus carinatum | □ EEG: | |
| Gastrointestinal Findings | □ Pectus excavatum | □ EMG: | |
| Constipation | □ Polydactyly | ☐ MRI: | |
| □ Diarrhea □ Duodenal stenosis/atresia | ☐ Recurrent fractures | ☐ Muscle Biopsy: | |
| ☐ Exocrine pancreatic insufficiency | Rhabdomyolysis | □ Ultrasound: | |
| ☐ Failure to thrive | Scoliosis | Ultrasound: | |
| ☐ Feeding difficulties | Short stature | □ X-rays: | |
| ☐ Gastroesophageal reflux | Skeletal dysplasia | | |
| ☐ Hepatomegaly | Syndactyly | | |
| ☐ Inflammatory bowel disease | ☐ Tall stature | | |
| ☐ Intrahepatic biliary atresia | | Additional Clinical Findings: | |
| Laryngomalacia | | | |
| □ Nausea | Metabolic Findings | | |
| □ Pancreatitis | (Attached relevant lab reports/values) | | |
| ☐ Pyloric stenosis | ☐ Abnormal activity of mitochondrial | | |
| □ Splenomegaly | respiratory chain | | |
| ☐ Tracheoesohageal fistula | ☐ Abnormal Newborn Screen: | | |
| ☐ Vomiting | ☐ Abnormality of mitochondrial metabolism | | |
| | ☐ Elevated CPK | | |
| | ☐ Elevated hepatic transaminase | | |
| Genitourinary Findings | ☐ Hyperammonemia | | |
| □ Ambiguous genitalia | Hyperglycemia | | |
| ☐ Cryptorchidism | ☐ Hypoammonemia | | |
| ☐ Cystic renal dysplasia | Hypoglycemia | | |
| ☐ Horseshoe kidney | ☐ Increased serum pyruvate | | |
| ☐ Hydronephrosis | Lactic acidosis | | |
| ☐ Hypospadias | □ Plasma AA: | | |
| ☐ Inguinal hernia | ☐ Urine OA: | | |
| □Micropenis | | | |
| □ Nephrolithiasis | | | |

☐ Polycystic kidney disease☐ Renal agenesis

☐ Umbilical hernia



First Name Last Name Date of Birth

For the purposes of this consent, "I", "my", and "your" will refer to me or to my child, including my unborn child, if my child is the person for whom the healthcare provider has ordered testing.

PURPOSE OF THIS TEST

The purpose of this test is (a) to see if I may have a genetic variant or chromosome rearrangement causing a genetic disorder; or (b) to evaluate the chance that I will develop or pass on a genetic disorder in the future. If I already know the specific gene variant(s) or chromosome rearrangement that causes the genetic disorder in my family, I agree to inform the laboratory of this information.

WHAT TYPE OF TEST RESULTS CAN I EXPECT FROM GENETIC TESTING?

- 1. <u>Positive</u>: A change in your DNA was found, which is very likely the cause of your features/symptoms. This is the most straightforward test result, which can be used as the basis to test other family members to determine their chances of having either the disease or a child with the disease.
- 2. Negative: No variants were found to explain your symptoms. This does not mean that you do not have a genetic condition. It is still possible that there is a genetic variant not found by the test that was ordered. Your healthcare provider or genetic counselor may discuss more testing either now or in the future.
- 3. <u>Variant of Uncertain Significance (VUS)</u>: A change in a gene was found. However, we are not sure whether this variant is the cause of your symptoms/features. More information is needed. We may suggest testing other family members to help figure out the meaning of the test result.
- 4. <u>Unexpected Results</u>: In rare instances, this test may reveal an important genetic change that is not directly related to the reason for ordering this test. For example, this test may find you are at risk for another genetic condition I am not aware of or it may indicate differences in the number or rearrangement of sex chromosomes. We may disclose this information to the ordering healthcare provider if it likely affects medical care.

Because medical and scientific knowledge is constantly changing, new information that becomes available may supplement the information GeneDx used to interpret my results. Healthcare providers can contact GeneDx at any time to discuss the classification of an identified variant.

WHAT IS TRIO/DUO-BASED GENETIC TESTING?

For some genetic tests, including samples from the biological parents and/or other biological relatives along with the patient's sample can help with the interpretation of the test results. These tests are often referred to as "trio tests" since they typically include samples from the patient and both parents.

Samples from relatives should be submitted with the patient's sample. Clinical information must be provided for the patient and any relative who submits a sample.

I understand that GeneDx will use the relative sample(s) when needed for the interpretation of my test results and that my test report may include clinical and genetic information about a relative when it is relevant to the interpretation of the test results. I further understand that relatives will not receive an independent analysis of data nor a separate report.

RISKS AND LIMITATIONS OF GENETIC TESTING

- 1. In some cases, testing may not identify a genetic variant even though one exists. This may be due to limitations in current medical knowledge or testing technology.
- 2. Accurate interpretation of test results may require knowing the true biological relationships in a family. I understand that if I fail to accurately state the biological relationships in my family, it could lead to incorrect interpretation of the test results, incorrect diagnoses, and/or inconclusive test results. If genetic testing reveals that the true biological relationships in a family are not as I reported them, including non-paternity (the reported father is not the biological father) and consanguinity (the parents are related by blood), I agree to have these findings reported to the healthcare provider who ordered the test.
- 3. Although genetic testing is highly accurate, inaccurate results may occur. These reasons include, but are not limited to mislabeled samples, inaccurate reporting of clinical/medical information, rare technical errors, or other reasons.
- 4. I understand that this test may not detect all of the long-term medical risks that I might experience. The result of this test does not guarantee my health and that additional diagnostic tests may still need to be done.
- 5. I agree to provide an additional sample if the initial sample is not adequate.

PATIENT CONFIDENTIALITY AND GENETIC COUNSELING

It is recommended that I receive genetic counseling before and after having this genetic test. I can find a genetic counselor in my area at www.nsgc.org. Further testing or additional consultations with a healthcare provider may be necessary.

To maintain confidentiality, test results will only be released to the referring healthcare provider, the ordering laboratory, to me, to other healthcare providers involved in my care, diagnosis and treatment, or to others with my consent or as permitted or required by law. Federal laws prohibit unauthorized disclosure of this information. More information can be found at: www.genome.gov/10002077

INTERNATIONAL SAMPLES

If I reside outside the United States, I attest that by providing a sample for testing, I am not knowingly violating any export ban or other legal restriction in the country of my residence.

SAMPLE RETENTION

After testing is complete, my sample may be de-identified and be used for test development and improvement, internal validation, quality assurance, and training purposes. GeneDx will not return DNA samples to you or to referring healthcare providers, unless specific prior arrangements have been made.

I understand that samples from residents of New York State will not be included in the de-identified research studies described in this authorization and GeneDx will not retain them for more than 60 days after test completion, unless specifically authorized by my selection. The authorization is optional, and testing will be unaffected if I do not check the box for the New York authorization language. GeneDx will not perform any tests on the biological sample other than those specifically authorized.

DATABASE PARTICIPATION

De-identified health history and genetic information can help healthcare providers and scientists understand how genes affect human health. Sharing this deidentified information helps healthcare providers to provide better care for their patients and researchers to make new discoveries. GeneDx shares this type of information with healthcare providers, scientists, and healthcare databases. GeneDx will not share any personally identifying information and will replace the identifying information with a unique code not derived from any personally identifying information. Even with a unique code, there is a risk that I could be identified based on the genetic and health information that is shared. GeneDx believes that this is unlikely, though the risk is greater if I have already shared my genetic or health information with public resources, such as genealogy websites.



First Name Last Name Date of Birth

EXOME/GENOME SEQUENCING SECONDARY FINDINGS

- · Applicable only for full exome sequencing and genome sequencing tests
- Does not pertain to Xpanded® or Slice tests

As many different genes and conditions are analyzed in an exome or genome sequencing test, these tests may reveal some findings not directly related to the reason for ordering the test. Such findings are called "incidental" or "secondary" and can provide information that was not anticipated.

Secondary findings are variants, identified by an exome or genome sequencing test, in genes that are unrelated to the individual's reported clinical features.

The American College of Medical Genetics and Genomics (ACMG) has recommended that secondary findings identified in a specific subset of medically actionable genes associated with various inherited disorders be reported for all probands undergoing exome or genome sequencing. Please refer to the latest version of the ACMG recommendations for reporting of secondary findings in clinical exome and genome sequencing for complete details of the genes and associated genetic disorders. Reportable secondary findings will be confirmed by an alternate test method when needed.

WHAT WILL BE REPORTED FOR THE PATIENT?

All pathogenic and likely pathogenic variants associated with specific genotypes identified in the genes (for which a minimum of 10X coverage was achieved by exome sequencing or a minimum of 15X coverage was achieved by genome sequencing), as recommended by the ACMG.

WHAT WILL BE REPORTED FOR RELATIVES?

The presence or absence of any secondary finding(s) reported for the proband will be provided for all relatives analyzed by an exome or genome sequencing test.

LIMITATIONS

Pathogenic and/or likely pathogenic variants may be present in a portion of the gene not covered by this test and therefore are not reported. The absence of reportable secondary findings for any particular gene does not mean there are no pathogenic and/or likely pathogenic variants in that gene. Pathogenic variants and/or likely pathogenic variants that may be present in a relative, but are not present in the proband, will not be identified nor reported. Only changes at the sequence level will be reported in the secondary findings report. Larger deletions/duplications, abnormal methylation, triplet repeat or other expansion variants, or other variants not routinely identified by clinical exome and genome sequencing will not be reported.

FINANCIAL AGREEMENT AND GUARANTEE

For insurance billing, I understand and authorize GeneDx to bill my health insurance plan on my behalf, to release any information required for billing, and to be my designated representative for purposes of appealing any denial of benefits. I irrevocably assign to and direct that payment be made directly to GeneDx.

I understand that my out-of-pocket costs may be different than the estimated amount indicated to me by GeneDx as part of a benefit investigation. I agree to be financially responsible for any and all amounts as indicated on the explanation of benefits issued by my health insurance plan. If my insurance provider sends a payment directly to me for services performed by GeneDx on my behalf, I agree to endorse the insurance check and forward it to GeneDx within 30 days of receipt as payment towards GeneDx's claim for services rendered.

If I do not have health insurance, I agree to pay for the full cost of the genetic testing that was ordered by my healthcare provider and billed to me by GeneDx. I further understand and agree that, if I fail to make payment for genetic testing, in accordance with the payment policies of GeneDx, my account may be turned over to an external collection agency for non-payment. I agree to pay any associated collection costs, including attorney fees. By my signature on the GeneDx Test Requisition Form or at the bottom of this form, I accept full and complete financial responsibility for all genetic testing ordered by my healthcare provider.

MEDICARE

A completed Advance Beneficiary Notice (ABN) is required for Medicare patients, when applicable. Please visit our website, www.genedx.com/billing for more information.